Two incoming lawmakers plan to defend health equity from Trump administration cuts

The key political change was a sweep of Democratic victories in the midterm elections. Democrats gained control of both chambers of the 120th Congress. That matters because Congress can investigate executive policies, challenge agency decisions, and reject some funding proposals, even though the president retains veto power.

The change brought two lawmakers with direct scientific experience into Congress. Michigan Senator-elect Abdul El-Sayed studied health disparities, while incoming Georgia Representative Jasmine Clark is a microbiologist and former professor. Both said their work showed them why equity programs and research matter.

Their influence will still face limits. President Trump can veto legislation, and the White House said, “DEI is still dead.” Still, Democratic control could produce stronger oversight, more public questioning, and further resistance to grant cancellations, funding restrictions, and efforts to reduce diversity programs.

Abdul El-Sayed is Michigan’s senator-elect, an epidemiologist, and a former health-disparities researcher. His academic work examined disparities in maternal health and within the Arab American community. He brings research experience focused on how systems can produce unequal chances to live long, healthy lives.

Jasmine Clark is an incoming representative from Georgia, a microbiologist, and a former professor. She will be the first Black woman with a STEM Ph.D. in Congress. Her former laboratory studied HIV transmission, and she has taught students who benefited from diversity, equity, and inclusion programs.

Their scientific backgrounds give them firsthand experience with both research and education. El-Sayed emphasizes documenting unequal health outcomes. Clark emphasizes expanding opportunities for students and protecting international research partnerships. Both plan to use congressional roles to question policies affecting researchers and marginalized communities.

Health equity means that all communities should have a fair and just opportunity to be healthy. In medical research, it involves documenting unequal outcomes and identifying the systems that create or allow those differences. The goal is better evidence and better public policy.

Diversity, equity, and inclusion, or DEI, applies that principle to institutions such as universities, laboratories, and medical schools. It supports participation by people from different backgrounds, fair access to opportunities, and environments where people can contribute. Clark said DEI programs helped students discover scientific opportunities.

The article presents these ideas as connected but not identical. Health equity focuses on fair health outcomes and access. DEI focuses on representation, access, and inclusion in education and science. Supporters say both strengthen research and help institutions serve communities that have been overlooked or harmed.

The administration’s actions reached across research funding, education, and international collaboration. It terminated hundreds of grants intended to document or remedy medical inequities. It also shuttered programs designed to diversify the science workforce and investigated universities and medical schools over alleged discrimination against white and Asian applicants.

The administration also proposed cutting the National Institutes of Health budget, capping university overhead funding, and increasing political control over federal research money. Congress rebuked those proposals. The article additionally describes restrictions that forced a laboratory studying HIV transmission to pause some longitudinal studies in Africa.

Public support for health equity remains substantial. Philip Alberti reported that 75% of U.S. adults support the goal of all communities having a fair and just opportunity to be healthy. Among adults familiar with the term, 65% support health equity. Support crossed ideological and other demographic groups.

Grant terminations removed support for work meant to document and remedy medical inequities. Closing science-workforce programs also reduced structured opportunities intended to diversify research. Jennifer Jones said Congress should determine which communities and researchers were most harmed, because the effects raise questions of justice and equity.

International restrictions created a direct research disruption. Clark said her former HIV-transmission laboratory had to pause some longitudinal studies in Africa because international collaborations were restricted. A pause can interrupt long-term data collection and weaken researchers’ ability to follow changes over time, though the excerpt gives no further results.

The supplied excerpt does not explain consequences from screening for DEI-related words. It therefore cannot support a specific claim about that practice. More broadly, the article suggests Congress may investigate affected researchers and communities, while Democrats push back against policies that limit equity research and collaboration.

Congress can respond through oversight, hearings, investigations, and funding decisions. Clark said she wanted a seat on the House oversight committee and planned to question appointees such as Health Secretary Robert F. Kennedy Jr. Lawmakers can also examine which researchers and communities were affected by terminated grants and restrictions.

Congress has already rebuked proposals to cut the NIH budget, cap university overhead funding, and give the administration more political control over federal research money. Democratic control of both chambers could produce additional investigations and resistance. It could also raise public accountability for agency decisions.

The president’s veto power remains a major limit. Even if both chambers approve a bill, President Trump can block it. Democrats would need enough support to overcome a veto, which the article describes as unlikely or difficult. Oversight and public scrutiny may therefore be more practical tools than passing new laws.

The Tuskegee syphilis experiment is an important warning because it involved African American men whose syphilis treatment was withheld. The study lasted from 1932 to 1972 and included nearly 400 men. It demonstrates how researchers and public institutions can exploit marginalized communities and violate basic medical ethics.

Clark compared the Tuskegee experiment with the administration’s repeated push for a controversial hepatitis B vaccine study in Guinea-Bissau. Her comparison does not establish that the studies were identical. Instead, it shows why historical abuses matter when officials evaluate research involving communities with less power.

Tuskegee provides a standard for asking whether participants are treated fairly, informed properly, and protected from harm. The article does not give details about the Guinea-Bissau study’s design or findings. It shows, however, that historical accountability shapes Clark’s planned congressional oversight of medical research.